Document is current

Any future updates will be listed below

Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor

Crossref DOI link: https://doi.org/10.1007/s10637-019-00757-9

Published Online: 2019-03-23

Published Print: 2019-06-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark